Skip to main content
Image
Photo of Committee panel

Hearing on “Modernizing FDA’s Regulation of Over-the-Counter Drugs,” Subcommittee on Health (September 13, 2017)

Date:
Location:
2322 Rayburn House Office Building

The Subcommittee on Health held a hearing on Wednesday, September 13, 2017, at 10:15 a.m. in 2322 Rayburn House Office Building. The hearing is entitled “Modernizing FDA’s Regulation of Over-the-Counter Drugs.” 

Witnesses

 

Livestream

 

Key Documents

Memorandum from Ranking Member Pallone to the Subcommittee on Health

Opening Statement of Ranking Member Pallone as prepared for delivery

Preliminary Transcript

 

Legislation

H.R. __, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2017, To amend the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application, and for other purposes.

 

Witnesses

Panel I:
Dr. Janet Woodcock, M.D.
Director, Center for Drug Evaluation and Research
Food and Drug Administration

Testimony

 

Panel II:
Scott Melville
President and CEO
Consumer Health Products Association

Testimony

 

Kirsten Moore
Project Director, Health Care Products
The Pew Charitable Trusts

 

Michael Werner
Partner
Holland & Knight, on behalf of the Public Access to SunScreens (PASS) Coalition

Testimony


Gil Roth
President
Pharma & Biopharma Outsourcing Association

Testimony


Bridgette L. Jones, MD, FAAP
Chair, American Academy of Pediatrics Committee on Drugs
Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine

Testimony

Issues:Health